INNOVENT BIO (01801) has completed a global strategic cooperation with Takeda Pharmaceuticals and has issued 6.9138 million shares under general authorization.

INNOVENT BIO (01801) announced that it has reached a global strategic cooperation agreement with Takeda Pharmaceuticals (through Takeda Pharmaceuticals International AG, a wholly-owned subsidiary of Takeda). All necessary conditions for the licensing, options, cooperation agreements, and share issuance agreement have been met or waived. Therefore, the licensing, options, and cooperation agreements have been completed, and the share issuance agreement will be completed on December 4, 2025. After the completion of the share issuance agreement, the company will issue and distribute 6.9138 million shares to the subscribers, representing approximately 0.40% of the company's issued share capital after the issuance of the subscribed shares. The total amount raised from the issuance and distribution of subscribed shares is approximately HK$778 million (calculated based on a subscription price of HK$112.56 per share), with a net amount of approximately HK$777 million.